ACT1 peptide

ACT1 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-RQPKIWFPNRRKPWKKRPRPDDLEI-OH

H-Arg-Gln-Pro-Lys-Ile-Trp-Phe-Pro-Asn-Arg-Arg-Lys-Pro-Trp-Lys-Lys-Arg-Pro-Arg-Pro-Asp-Asp-Leu-Glu-Ile-OH

25

95.19%

C₁₅₀H₂₃₈N₄₈O₃₄

3257.78

Synthetic

Powder

ACT1 (α–connexin carboxyl-terminal) is a membrane-permeant peptide incorporating the last nine amino acids of the Cx43 CT, and it is linked to an antennapedia internalization sequence (RQPKIWFPNRRKPWKKRPRPDDLEI). ACT1 is shown to accelerate wound closure, enhance epidermal complexity, reduce granulation tissue area and increase breaking strength and extensibility of skin following cutaneous wounding in mice, which indicates that the Cx43 CT-peptide ACT1 promotes regenerative healing of cutaneous wounds. The peptide may have applications in tissues other than skin, including heart, cornea and spinal cord.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Ghatnekar GS, O'Quinn MP, Jourdan LJ, Gurjarpadhye AA, Draughn RL, Gourdie RG. Connexin43 carboxyl-terminal peptides reduce scar progenitor and promote regenerative healing following skin wounding. Regen Med. 2009 Mar;4(2):205-23. doi: 10.2217/17460751.4.2.205. PMID: 19317641; PMCID: PMC2720252.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.